Troniz500 mg

Troniz is a nitroimidazole derivative with antiprotozoal and antibacterial (anti-anaerobic) activity. Its uses can be classified by strength of evidence as follows:

Established / Widely Approved Uses

• Intestinal amoebiasis (amoebic dysentery) caused by Entamoeba histolytica
• Amoebic liver abscess
• Giardiasis (intestinal infection caused by Giardia lamblia/intestinalis)
• Trichomoniasis, a sexually transmitted infection caused by Trichomonas vaginalis (both symptomatic patients and their sexual partners are typically treated)
• Bacterial vaginosis associated with anaerobic organisms
• Treatment of infections caused by susceptible anaerobic bacteria, including intra-abdominal, pelvic, and post-surgical anaerobic infections, usually as part of combination therapy when mixed aerobic-anaerobic infection is suspected

Adjunct / Prophylactic Use

• Perioperative antibiotic prophylaxis to prevent postoperative anaerobic infection in colorectal, gynaecological, and other surgery with a risk of anaerobic contamination (given as a single pre-operative dose, usually alongside an agent covering aerobic organisms)

Troniz is not approved or marketed in the United States, so it does not carry a US FDA label; the uses above reflect established international prescribing practice and guideline-supported indications, including use in South Asian countries such as Bangladesh.

Each formulation contains Ornidazole INN (International Nonproprietary Name) as the active pharmaceutical ingredient. Ornidazole is manufactured and marketed in several dosage forms, including:

• Film-coated tablets (commonly 500 mg)
• Oral suspension for paediatric or weight-based dosing
• Intravenous (IV) infusion, ready-to-use solution (commonly 500 mg/100 mL), for patients unable to take oral medication

Exact strength, excipients, and pack size vary by manufacturer and brand; always check the product label of the specific formulation dispensed.

Troniz is a synthetic 5-nitroimidazole derivative, structurally related to metronidazole and tinidazole, developed to treat protozoal and anaerobic bacterial infections. It exhibits broad activity against protozoan parasites (such as Entamoeba histolytica, Giardia lamblia, and Trichomonas vaginalis) as well as many obligate anaerobic bacteria.

Compared with metronidazole, Troniz has a longer plasma half-life, which allows shorter treatment courses (including single-dose regimens) for some indications, and it is generally considered to be well tolerated. It is available for oral and intravenous use and is widely prescribed across South Asia, Southeast Asia, and other regions, including Bangladesh, though it is not marketed in the United States.

Nitroimidazole derivative — Antiprotozoal and antibacterial (anti-anaerobic) agent. Troniz belongs to the same pharmacological group as metronidazole, tinidazole, and secnidazole.

Mechanism of Action

Ornidazole diffuses into susceptible anaerobic and microaerophilic organisms, where its nitro group is reduced by intracellular redox (ferredoxin-like electron transport) proteins that are present only in anaerobic/microaerophilic metabolism. This reduction generates reactive intermediates that bind to and damage microbial DNA, disrupting its helical structure and inhibiting nucleic acid synthesis, which leads to cell death of the parasite or bacterium. Aerobic human cells and aerobic bacteria lack this reducing environment, giving the drug selective toxicity against anaerobes and protozoa.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed after oral administration (oral bioavailability approximately 90%); peak plasma concentration is reached in about 1-3 hours.
• Distribution: Widely distributed into body tissues and fluids, including the CNS, bile, saliva, and vaginal secretions; crosses the placenta and is excreted into breast milk.
• Metabolism: Extensively metabolised in the liver via oxidation, hydroxylation, and conjugation.
• Elimination half-life: Approximately 12-14 hours, longer than metronidazole, which permits once- or twice-daily dosing and short-course regimens.
• Excretion: Mainly via urine (as metabolites), with a smaller fraction eliminated in faeces.

Troniz tablets may be taken with or without food, though taking them with food or a full glass of water can reduce stomach upset. Tablets should be swallowed whole and not crushed or chewed unless the product labelling states otherwise. Oral suspension should be shaken well and measured using the calibrated measuring device provided.

The intravenous (IV) infusion form of Troniz is administered by slow intravenous infusion under medical supervision (typically over 30-60 minutes) and must not be given as a rapid IV push. It should be inspected visually for particulate matter or discolouration before use.

Avoid alcohol during treatment with Troniz and for at least 3 days after the last dose (see Interactions and Precautions).

The following are clinically significant interactions with Troniz:

• Alcohol: May cause a disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia); avoid alcohol during and for at least 3 days after treatment.
• Oral anticoagulants (e.g., warfarin): Troniz may potentiate the anticoagulant effect, increasing bleeding risk; prothrombin time/INR should be monitored and the anticoagulant dose adjusted if needed.
• Phenytoin: Mutual interaction reported — Troniz may alter phenytoin metabolism and phenytoin may affect Troniz levels; monitor for altered effect of either drug.
• Lithium: Concurrent use may increase serum lithium levels and risk of lithium toxicity; monitor lithium levels if co-administered.
• Hepatic enzyme inducers (e.g., phenobarbital, rifampicin): May accelerate metabolism of Troniz, reducing its plasma concentration and efficacy.
• Disulfiram and other CNS-active agents: Concomitant use with disulfiram-like agents may increase the risk of neuropsychiatric reactions; avoid combined use.

Inform your physician about all medicines, supplements, and alcohol use before starting Troniz.

Most adverse effects of Troniz are mild and transient. Reported side effects include:

Common

• Nausea, vomiting, epigastric discomfort
• Metallic or bitter taste in the mouth
• Headache, dizziness, drowsiness

Less Common

• Diarrhoea, dry mouth
• Peripheral neuropathy (tingling, numbness) with prolonged or high-dose therapy — see Precautions
• Skin rash, pruritus

Rare but Serious

• Hypersensitivity reactions, including angioedema
• Leukopenia (usually reversible on stopping the drug)
• Seizures or transient central nervous system disturbances (mainly with high-dose or prolonged therapy)

Seek medical attention promptly if severe rash, breathing difficulty, unusual bleeding/bruising, or persistent numbness/tingling occurs.

Pregnancy: Troniz is contraindicated in the first trimester of pregnancy. In the second and third trimesters, Troniz should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use at any stage of pregnancy, and alternative agents may be preferred where possible.

Lactation: Troniz is excreted into breast milk. Breastfeeding mothers should consult their physician before use; a temporary interruption of breastfeeding during treatment and for a short period afterward may be advised, depending on the dose and duration of therapy.

• Complete the full course: Take Troniz exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• Hepatic impairment: Troniz is extensively metabolised by the liver; dose reduction and extended dosing intervals are recommended in patients with significant hepatic impairment, with clinical monitoring.
• Neurological symptoms: Peripheral or central neuropathy (numbness, tingling, ataxia, confusion, seizures) can occur, particularly with prolonged or high-dose therapy; discontinue and seek medical advice if such symptoms develop.
• Blood dyscrasias: Monitor complete blood counts during prolonged or repeated courses of therapy.
• CNS disease: Use with caution in patients with a history of epilepsy or other organic CNS disease; avoid high-dose/prolonged therapy in such patients (see Contraindications).
• Alcohol: Avoid alcohol during treatment and for at least 3 days afterward due to the risk of a disulfiram-like reaction.
• Driving/operating machinery: Troniz may cause dizziness or drowsiness; use caution until the effect on the individual is known.

Overdose of Troniz may cause exaggerated side effects such as nausea, vomiting, ataxia, disorientation, and, rarely, seizures. There is no specific antidote.

If overdose is suspected, seek immediate medical attention or contact a poison control centre/emergency services right away. Management is supportive and symptomatic, and should be carried out under medical supervision; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.

• Renal impairment: No routine dose adjustment is generally required in mild-to-moderate renal impairment, as Troniz is mainly hepatically metabolised; caution and physician judgement are advised in severe renal impairment or dialysis patients.
• Hepatic impairment: Dose reduction and longer dosing intervals are recommended (see Precautions & Warnings).
• Elderly: No specific dose adjustment is generally required, but elderly patients may be more susceptible to neurological adverse effects; monitor closely, especially with prolonged therapy.
• Pregnancy and lactation: See Pregnancy & Lactation section — contraindicated in the first trimester; use later in pregnancy and during breastfeeding only under medical advice.
• Children: See Pediatric Uses section for weight-based dosing and safety considerations.

Duration of Troniz therapy depends on the indication: single-dose regimens are used for uncomplicated giardiasis and trichomoniasis; 5-7 days for intestinal amoebiasis; up to 10 days for amoebic liver abscess or anaerobic bacterial infections; and a single peri-operative dose for surgical prophylaxis. The treating physician determines the exact duration, and the full prescribed course should always be completed even if symptoms improve earlier.

Nitroimidazoles; Antiprotozoal agents; Antibacterial agents (anti-anaerobic)

Ornidazole is selectively reduced inside anaerobic and microaerophilic organisms, generating cytotoxic intermediates that damage microbial DNA and inhibit nucleic acid synthesis, leading to parasite/bacterial cell death. Aerobic human cells are not affected in the same way, giving the drug its selective antimicrobial action.

Troniz is used in children for amoebiasis and giardiasis with weight-based dosing (generally 25-40 mg/kg/day, divided as appropriate for the indication, or as a single dose for giardiasis), under the supervision of a paediatrician. Oral suspension formulations facilitate accurate weight-based dosing in younger children who cannot swallow tablets.

Safety and efficacy in neonates and infants below the age typically studied have not been well established; use in this age group should be undertaken only when clearly necessary and under close medical supervision. As with adults, the full prescribed course should be completed, and the medicine should not be shared or dosed without medical advice.